BioPharma Dive October 28, 2024
Buying Aliada Therapeutics would hand AbbVie a clinical-stage Alzheimer’s medicine and a drugmaking technology that may be useful for a variety of brain diseases.
AbbVie has agreed to acquire a young company with drugmaking technology from Johnson & Johnson and an experimental treatment for Alzheimer’s disease that’s in the first stage of human testing.
The deal, announced Monday, is expected to close by the end of the year, and has AbbVie buying all the outstanding shares of Aliada Therapeutics for $1.4 billion in cash. A private company, Aliada formed in 2021 with seed funding from J&J’s venture arm and the investment firm RA Capital Management.
Aliada has a license to a technology J&J scientists created to get drugs across a...
Today's Sponsors
Today's Sponsor